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Although extensive angiogenesis takes place in glial tumors, antiangiogenic therapies have remained without the expected success.
In the peripheral circulation of glioma patients, increased numbers of endothelial precursor cells (EPCs) are present, potentially
offering targets for antiangiogenic therapy. However, for an antiangiogenic therapy to be successful, the therapy should specifically
target glioma-related EPC subsets and secreted factors only.Here, we compared the EPC subsets and plasma factors in the peripheral
circulation of patients with gliomas to acute myocardial infarctions. We investigated the five most important EPC subsets and 21
angiogenesis-related plasma factors in peripheral blood samples of 29 patients with glioma, 14 patients with myocardial infarction,
and 20 healthy people as controls, by FACS and Luminex assay. In GBM patients, all EPC subsets were elevated as compared to
healthy subjects. In addition, HPC and KDR+ cell fractions were higher than in MI, while CD133+ and KDR+CD133+ cell fractions
were lower. There were differences in relative EPC fractions between the groups: KDR+ cells were the largest fraction in GBM,
while CD133+ cells were the largest fraction in MI. An increase in glioma malignancy grade coincided with an increase in the
KDR+ fraction, while the CD133+ cell fraction decreased relatively. Most plasma angiogenic factors were higher in GBM than in
MI patients. In both MI and GBM, the ratio of CD133+ HPCs correlated significantly with elevated levels of MMP9. In the GBM
patients, MMP9 correlated strongly with levels of all HPCs. In conclusion, the data demonstrate that EPC traffic in patients with
glioma, representing neoplasia, is different from that in myocardial infarction, representing tissue regeneration. Glioma patients
may benefit from therapies aimed at lowering KDR+ cells and HPCs.
1. Introduction
Although gliomas are among the most vascularized tumors,
results of antiangiogenic therapies have been disappointing
[1]. Antiangiogenic drugs like Bevacizumab act against VEGF
and address sprouting angiogenesis (i.e., the formation of
new branches from existing blood vessels). There are various
reasonswhyVEGFblockers like Bevacizumab fail in stopping
tumor progression. One reason is that these drugs act against
a single step in the complex process of neovascularization
that can be compensated for by employing alternative routes
of vessel formation [2]. Simultaneously, targeting these alter-
native routes may result in more successful antiangiogenic
therapeutic strategies. Apart from sprouting angiogenesis,
circulating endothelial progenitor cells (EPCs) stimulate
neovascularization by vasculogenesis, i.e., de novo formation
of blood vessels [3–6]. Although these circulating cells are
interesting targets for antiangiogenic strategies, there are only
scarce data on their frequencies in glioma patients [7]. Since
EPCs are involved in physiological tissue repair, therapeutic
interventions should ideally not intervene with the normal
function of EPCs. EPCs are mobilized by factors secreted by
ischemic or neoplastic tissues [8]. Chemoattractants guide
EPCs to their target tissues, where they exit from blood
vessels and fuel angiogenesis by secreting proangiogenic
factors. A subset of EPCs differentiates into endothelial cells
and becomes part of the vessel wall [9].
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EPCs aid significantly in physiologic tissue regeneration
[4]. Following acute myocardial infarction (MI) for instance,
EPC subsets are mobilized by the release of proangiogenic
factors and chemoattractants [10–13]. HPCs and CD133+ cells
are engaged in tissue repair following the acute stage of MI
[14–16]. In cancer, EPCs participate in tumor vascularization
[17, 18], are associated with tumor progression [19], and
may diminish the effects of chemotherapy, while blood EPC
levels correlate negatively with survival [20]. In the peripheral
circulation of both acuteMI and (high grade) gliomapatients,
increased levels of circulating EPCs were demonstrated [7].
While various circulating EPC subsets were studied in the
context of MI, limited studies concerning glioma patients
are available [7, 21]. Moreover, there are only scarce data
correlating the frequency of circulating EPC subsets and
the levels of neovascularization-related plasma factors in
situations of tissue regeneration and neoplasia [22, 23].
In the present study, we aimed to find new targets
for antiangiogenic strategies for glioma patients that would
minimally interfere with normal tissue repair. To that aim,
we compared the frequency of circulating EPC subsets
and plasma levels of a set of chemoattractants, mobiliza-
tion factors, and angiogenic factors involved in neovas-
cularization in patients with glioma and in patients who
suffered from a recent MI. The reason we chose patient
with MI to represent the EPC response in acute ischemic
tissue repair is the availability of ample literature showing
a significant increase in circulating EPCs in this group of
patients. We considered including patients with ischemic
stroke as a model for EPC response in acute ischemia,
but since the literature is much less abundant in this
patient group, and since the EPC response in ischemic
stroke patients is not unequivocally elevated [7, 24], we
decided against this. Blood from healthy adults was used
as control. We used an optimized, highly sensitive four-
marker-based FACS protocol, allowing for the accurate
determination of the EPC subsets [25]. We investigated the
frequencies of HPCs (CD34+CD133+/−CD45dim), KDR+ cells
(KDR+CD34−CD133−), CD133+ cells (CD133+CD34−KDR−),
KDR+CD133+ cells (KDR+CD133+CD34−), and circulating
endothelial cells (CECs; CD34brightKDR+CD45−CD133−).
In addition, we distinguished between CD133bright HPCs,
a more primitive phenotype of HPCs that is linked with
higher proangiogenic capacity [23, 26, 27], and CD133−HPCs
[11].
2. Material & Methods
This study was approved by the Medical Ethics Committee
of the Erasmus Medical Center, Rotterdam, The Netherlands
(MEC-2011-313), and performed in adherence to the Code of
Conduct of the Federation of Medical Scientific Societies in
the Netherlands (http://www.federa.org/codes-conduct).
2.1. Blood Sampling and Handling. Based on a previous study
from our group, we anticipated to require between 10 and
25 subjects in each patient and control group to determine
statistically significant changes in the frequency of circulating
EPC subsets [7]. Since our current study uses more stringent
inclusion criteria (treatment-naı¨ve patients with a new diag-
nosis of glioblastoma, grade II/III astrocytoma, myocardial
infarction patients within 1-10 days after acute myocardial
infarction) and a much more advanced and fine-tuned FACS
protocol [25], we expected that fewer inclusion would suffice
to determine statistically significant changes between EPC
subsets. For this reason, we aimed to include between 10 and
20 patients in each group of patients and controls.
Blood samples of treatment-naı¨ve patients with radiolog-
ically suspected first-episode malignant intracranial tumors
were obtained from the Department of Neurosurgery, Eras-
mus MC. The blood was sampled prior to (diagnostic)
surgery and chemo- or radiotherapy. Only patients with a
histologically confirmed diagnosis of gliomawere included in
the current study. In retrospect, out of 38 patients with radio-
logically suspect malignant intracranial tumors included for
FACS analysis, 20 patients received a definitive diagnosis of
glioblastoma (GBM), 5 patients of astrocytoma grade II/III
(AII/III). Nine patients were diagnosed with brainmetastases
and 4 patients with various other diagnoses (these 13 patients
were excluded from our study). One GBM patient was
excluded because of radiotherapy prior to blood sampling
and surgery, and one GBM patient was excluded due to
technical problems during FACS analysis.
We chose not to group together astrocytoma grade II/III
and glioblastoma patients due to the differences between
these tumor entities in neovascularization. While in astro-
cytoma neovascularization is not or only modestly increased
and blood vessels are histologically largely similar to normal
blood vessels, in glioblastoma there is an extremely high
density of blood vessels (up to the point that glioblastomas are
among the most vascularized solid tumors), which are hap-
hazardly organized and histologically anomalous (“microvas-
cular proliferation”). We expected that because of this: we
could find large differences in the role and frequency of EPCs
in the circulation of astrocytoma and glioblastoma patients.
Blood samples from patients who had suffered a recent
MI (1-10 days prior to sampling) were received from the
Department of Cardiology/Thoracic Center, Erasmus MC.
Blood samples from healthy blood donors were obtained via
the Sanquin Blood Bank. Age and sex distributions are shown
in Tables 1(a) and 1(b). A total of 84 blood samples were
included (70 were used for the analysis of chemoattractants
and proangiogenic factors and 57 for FACS analysis of EPC
subsets). For 43 of the patients, both FACS analysis and
plasma marker analysis were carried out. For FACS analysis,
we finally included blood samples of 14 MI patients, 18GBM
patients, 5 AII/III patients, and 20 healthy controls (HC).The
mean age of GBM patients was 66 years, for MI patients 60
years, and for HC 54 years. GBM patients were significantly
older than patients with AII/III (mean ages 66 vs. 45,
respectively) reflecting the characteristic age distribution for
patients with these tumors.
For each subject, 12-30ml of venous EDTA blood (BD
vacutainer) was collected. Two ml of whole blood was
immediately centrifuged at 400 rcf for 10 minutes to isolate
platelet-rich plasma (PRP). Next, PRP was centrifuged at
3,000 rcf for 15 minutes. Platelet-poor plasma (PPP) was
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Table 1: Blood samples used for (a) FACS analysis and (b) Luminex
analysis. A total of 84 blood samples were included in the study. For
43 of these samples, both FACS and Luminex analyses were done.
(a)
FACS Age Sex
Samples N Mean SD Minimum Maximum m/f
HC 20 54 12 22 69 15/5
MI 14 60 11 38 77 11/3
AII/III 5 45 11 32 58 0/5
GBM 18 66 10 45 79 9/9
Total 57
(b)
Luminex Age Sex
Samples N Mean SD Minimum Maximum m/f
HC 20 59 7 38 69 15/5
MI 14 60 11 38 77 11/3
AII/III 7 53 12 35 69 2/5
GBM 29 65 9 45 81 16/13
Total 70
isolated and stored at -80∘C. Blood samples were stored at
room temperature in the dark no longer than 18 hours before
further FACS analysis.
2.2. FACS Analysis. HPCs and CECs were analyzed by
FACS as described before [25]. Additional gates were set
to identify KDR+CD34−CD133− cells, CD133+CD34−KDR−
cells, and KDR+CD133+CD34− cells. In brief, peripheral
blood mononuclear cells (PBMCs) were isolated from whole
blood using Ficoll Paque plus (GE Healthcare). PBMCs
were incubated with 10% mouse serum on ice to block
aspecific antibody binding. CD34-FITC (Southern Biotech),
CD133-PE (MACS Miltenyi), KDR-APC (MACS Miltenyi),
and CD45-Viogreen (MACS Miltenyi) were used to stain
PBMCs. Cells were washed twice to remove excess antibody
and resuspended in FACS sorting buffer (PBS+10% BSA).
Hoechst was used as viability dye to exclude dead cells from
the analysis. For FACS analysis, we used the BD FACS Aria
III. For the initial setup, we analyzed positive control samples
using fluorescence minus one as well as isotype controls for
every antibody used.We acquired the equivalent of 10-50∗106
PBMCs in each analysis using our previously published strat-
egy for the detection of rare cells [25]. We gated the following
populations: CD34+CD133+/−CD45dimcells (HPCs), which
we subdivided into CD133negative, CD133dim, and CD133bright
subpopulations. In addition, CD34brightKDR+CD45−CD133−
cells (CECs) were gated as described in detail in [25]. In
addition, CD133+ cells (gated as CD34− and KDR−), KDR+
cells (gated as CD133− and CD34−), and KDR+CD133+ cells
(gated as CD34−) were analyzed (setup and gating strategy
similar to [25]). To quantify subtypes of EPCs, each pop-
ulation was represented as absolute cell numbers in 1∗106
CD45+ PBMCs. The nonparametric Mann–Whitney U test
(SPSS version 24) was used to analyze differences between
the groups. Extreme outliers were excluded from the analysis
(Figure 1).
2.3. Measuring Plasma Chemoattractants and Angiogenic
Factors. The concentrations of 21 plasma factors related to
EPC biology and neovascularization were measured. The
plasma factors were selected based on their key func-
tions in EPC-mediated neovascularization: mobilization and
chemotactic factors (CXCL12, CSF2, and CSF3), de-adhesion
and invasion factors (MMP2, MMP9), and proangiogenic
factors/microenvironment regulators (VEGFA, KITL, vWF,
EGF, FGFb, EPO, Ang2, Ang1, BDNF, VCAM1, PDGFBB,
tenascin-c, periostin, HGF, and PGF) [22, 28–33]. The
angiogenic factors either directly stimulate angiogenesis or
represent regulators of angiogenesis like MMP-2, MMP-9,
tenascin-c, and periostin that aid in generating a microenvi-
ronment favoring neovascularization. The functional delin-
eations are, however, not strict and there is extensive overlap
in functions of the factors.The plasma factors were measured
in PPP using 3 different custom-mixed magnetic bead-based
MAGPIX-Luminex assays from R&D (see Additional File
1). Analyses were performed on PPP, diluted as recom-
mended by the company (R&D Systems, Abingdon, UK).
Because of low concentrations, the levels of CSF2, CSF3,
vWF, VEGF, EGF, and CXCL12 were measured by their
raw mean fluorescence intensity (MFI) values. In order
to determine whether using MFI values yielded reliable
statistical results, we compared calculated concentrations of
markers with a high concentration, with their correspond-
ing MFI values. This yielded identical statistical results.
In addition, the results of the low concentration markers
(using their MFI values) fit with preexisting literature [34].
Therefore, the MFI values of these markers were added to
the data set. The nonparametric Mann–Whitney U test (SPSS
version 24) was used to analyze differences between the
groups.
2.4. Correlating Plasma Factors with EPC Frequencies in GBM
and MI. To determine if the levels of chemoattractants and
mobilization factors were related to EPC and CEC levels, we
conducted correlation analyses. Since the frequencies of EPCs
display a non-Gaussian distribution and since the correlation
between EPC frequencies and plasma factors proved to be
nonlinear, we used Spearman’s rho to calculate correlation
coefficients.
3. Results
3.1. EPCAbsolute Frequencies. In all groupsHPCs, KDR+ and
CD133+ cells represented the majority of circulating EPCs
(Figure 2). In patients with GBM and acute MI, all EPC
subsets were higher as compared to HC, except for the HPC
fraction in MI (Figures 1 and 3) . In GBM patients, KDR+
(Z=-2.0; p=0.04) andHPC levels (Z=-1.6; p=0.12) were higher
as compared to those in MI patients, while in MI patients
CD133+ (Z=-1.3; p=0.19) and KDR+CD133+ (Z=-2.0; p=0.02)
levels exceeded those in GBM patients.
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Figure 1: 	e frequencies of EPCs in patients included in the study. Boxplots of frequencies of EPCs (absolute amount in 1∗106 PBMCs).
Extreme outliers have been excluded from the graphs (extreme outliers excluded: HPCs: 2 (1 MI, 1 GBM); KDR+: 6 (3 MI, 3 HC); CD133+:
2 (1 MI, 1 GBM); KDR+CD133+: 1 GBM). (a) HPC levels are the highest in GBM patients. Levels are similar in HC and AII/III patients. (b)
KDR+ levels are the highest in GBM and increased in MI patients. Levels are similar in AII/III and HC. (c) CD133+ cells are the highest in
MI patients and elevated in GBM patients. Levels are similar in AII/III and HC. (d) KDR+CD133+ cells are the highest in MI patients and
elevated in GBMpatients. Levels are similar in AII/III andHC. (e)CECs are elevated in bothMI andGBMpatients.They are indistinguishable
between HC and AII/III. (f) The ratio of CD133bright/CD133- HPCs is highest in MI patients.
3.2. EPC Relative Fractions. The relative fractions of the
EPCs differed in the groups (Figure 2). In GBM, the largest
fraction of EPCs was KDR+ (57%), while in MI patients
the largest fraction was CD133+ cells (43%). In addition, in
GBM, the HPC fraction was twice as big as in MI, while
in MI, the KDR+CD133+ fraction was three times larger
than in GBM patients. The relative fractions of EPCs in
HC were similar to those in GBM. However, the absolute
numbers of circulating EPCs are significantly elevated in
GBM patients (Figure 1). Noticeably, absolute levels of EPCs
in AII/III patients were comparable to HC, while the relative
distribution of EPC subsets was very different: in AII/III
the fraction of CD133+ cells was significantly larger and that
of HPCs was significantly smaller than in HC. Comparing
AII/III with GBM, we found the KDR+ fraction increased
along with malignancy grade from 40% in AII/III to 57% in
Journal of Oncology 5
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Figure 2: Relative percentages of EPCs. Relative percentages of EPCs (median values) by patient group are shown in pie charts.
GBM.TheCD133+ cell fraction decreased from38% inAII/III
to 22% in GBM.
The KDR+CD133+ fraction in all groups was relatively
small (for all groups below 10%) and CECs were the smallest
population, with percentages below 1% for all groups.
3.3. Plasma Factors. There were considerable differences in
the concentrations of the various plasma factors between
the groups (Figure 4) . Both in GBM and MI patients, the
factors MMP9, HGF, and vWF were elevated in plasma
relative to HC. VCAM1 was specifically elevated in GBM,
while angiogenin and tenascin-c were specifically elevated
in MI, relative to HC. Nine factors were higher in HC than
in MI patients and only one factor, CXCL12, was higher
in HC than in GBM patients. Most plasma angiogenic
factors were higher in GBM than in MI patients. Ang2
and angiogenin levels were higher in MI patients compared
to GBM, while CSF2, CSF3, FGFb, EPO, PDGFBB, Ang1,
and the ratio Ang1/Ang2 were all higher in GBM than
in MI patients. Interestingly, the concentrations of plasma
factors in AII/III patients were indistinguishable from HC,
except for CXCL12, which was decreased in AII/III. See
Figure 4 .
3.4. Correlations Between Plasma Factors and EPC Frequen-
cies in GBM and MI. The Spearman correlations between
EPC subpopulations and plasma factors in patients with
gliomas, MI, and HC are shown in Additional File 2. In
GBM patients, MMP9 correlated strongly with HPC levels
(rho=0.62; p=0.03) and KDR+ levels correlated with VCAM1
plasma concentration (rho=0.64; p=0.04). In MI patients,
HPC levels correlated negatively with plasma concentrations
of CSF3 (rho=-0.76; p=0.002), VEGFA (rho=-0.56; p=0.04),
and PGF (rho=-0.61; p=0.02). CD133+ levels correlated nega-
tively withMMP2plasma concentration (rho=-0.59; p=0.03),
while tenascin-c concentration correlated positively with
both KDR+CD133+ levels (rho=0.60; p=0.03) and CD133+
levels (rho=0.57; p=0.03). Significant correlations for GBM
and MI are shown in Figure 5 .
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GBM vs MI Z P (2-tailed)
KDR+ 2.0 0.04
GBM > MIHPCs 1.6 0.12
CECs 0.8 0.45
CD133+ -1.3 0.19
MI > GBM
KDR+CD133+ -2.4 0.02
GBM vs HC Z P (2-tailed)
KDR+ 4.7 ≤0.001
GBM > HC
CECs 2.9 ≤0.001
KDR+CD133+ 2.3 0.02
CD133+ 2.2 0.03
HPCs 1.8 0.07
MI vs HC Z P (2-tailed)
KDR+CD133+ 4.0 ≤0.001
MI > HC
CD133+ 3.0 ≤0.001
CECs 1.8 0.07
KDR+ 2.0 0.04
HPCs 0.1 0.89
GBM vs AII/III Z P (2-tailed)
KDR+ 3.1 ≤0.001
GBM > AII/AIII
CECs 3.0 ≤0.001
KDR+CD133+ 2.2 0.03
HPCs 1.9 0.06
CD133+ 0.7 0.51
AII/III vs HC Z P (2-tailed)
CD133+ 0.7 0.46 AII/AIII > HC
KDR+ -0.4 0.72
HC > AII/AIII
HPCs -0.6 0.55
KDR+CD133+ -0.6 0.54
CECs -1.0 0.34
Figure 3: Diﬀerences in EPC frequencies between patients.
EPC levels were represented as absolute cell numbers in 1∗106
CD45+ PBMCs. The nonparametric Mann–Whitney U test (SPSS
version 24) was used to analyze differences between the groups
(p-values are 2-tailed). Direction of Z-score was adjusted as
follows: negative to positive when GBM levels were higher than
HC/MI/AII/AIII and when MI levels were higher than HC. The
heat-maps are based on the levels and directions of Z-scores
(red indicated higher levels of EPCs; blue indicated lower levels
of EPCs in each comparison). KDR+ : KDR+CD34−CD133−
cells. CD133+: CD133+CD34−KDR− cells. KDR+CD133+:
KDR+CD133+CD34− cells. HPCs: CD34+CD133+/−CD45dim.
CECs: CD34brightKDR+CD45−.
4. Discussion
We compared circulating EPC populations and plasma fac-
tors of patients with GBM and MI to pinpoint potential
differences in EPC biology that may lead to the development
of new therapeutic strategies directed against glioma-specific
neovascularization.
GBM vs MI Z P (2-tailed) 
FGFb 2.9 0.004 
GBM > MI 
CSF3 2.4 0.018 
PDGFbb 2.3 0.021 
EPO 2.3 0.022 
CSF2 2.1 0.040 
Ang1 1.9 0.055 
Angiogenin -2.0 0.045 
MI > GBM 
Ang2 -2.5 0.011 
GBM vs HC Z P (2-tailed) 
MMP9 4.5 ≤0.001 
GBM > HC 
vWF 3.9 ≤0.001 
HGF 2.7 0.008 
VCAM1 2.6 0.008 
CXCL12 -3.8 ≤0.001 HC > GBM 
MI vs HC Z P (2-tailed) 
vWF 4.0 ≤0.001 
MI > HC 
MMP9 3.6 ≤0.001 
HGF 3.2 ≤0.001 
Angiogenin 2.9 0.004 
Tenascin-C 2.1 0.036 
MMP2 -2.0 0.041 
HC > MI 
Ang1 -2.1 0.039 
CSF3 -2.1 0.039 
CXCL12 -2.1 0.036 
BDNF -2.3 0.021 
PDGFbb -2.3 0.021 
EPO -2.9 0.003 
FGFb -3.5 ≤0.001 
Figure 4: Diﬀerences in levels of plasma factors between patients.
Z-scores and p-values of differences in the levels of plasma
factors between patient and control groups (nonparametric
Mann–Whitney U test). Direction of Z-score was adjusted as
follows: negative to positive when GBM plasma levels of the factors
were higher than MI/HC and when MI levels were higher than HC.
The heat-maps are based on the levels and directions of Z-scores
(red indicated higher levels of plasma factors; blue indicated lower
levels of plasma factors in each comparison).
While there was a general elevation of EPC levels in both
GBM andMI patients compared to HC, we found differences
in specific EPC subsets between GBM and MI patients. In
GBMpatients, HPCs andKDR+ cells were elevated compared
to MI patients. In MI patients, KDR+CD133+and CD133+
cells were higher than in GBM patients. Increased levels
of CD133+ cells were described before in MI patients [35].
An increase in KDR+CD133+ cells was reported following
vascular damage due to burns or surgery [36], as well as
in GBM and patients with other tumors [19, 37]. Data on
circulating KDR+(CD34−CD133−) cells are largely lacking in
the literature. Increased levels of circulating KDR+ bone-
marrow-derived EPCs were reported in a cancer mouse
model [38], which is compatible with our findings in glioma
patients. Increased HPC levels were observed previously in
untreated GBM patients [39], while levels seem to normalize
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MI (n=14) CSF3 VEGFA MMP2 PGF Tenascin-C 
HPCs -0.76∗∗ -0.56∗ -0.61∗ 
0.60∗
CD133 + -0.59∗ 0.57∗
GBM (n=12) MMP9 VCAM1 
HPCs 0.62∗
KDR + 0.64∗
KD２+CD133+
Figure 5: Correlation between plasma factors and EPC subtypes. ∗∗Correlation is significant at the 0.01 level (2-tailed). ∗Correlation is
significant at the 0.05 level (2-tailed). We used Spearman’s rho to calculate correlation coefficients between plasma factor and EPC subtype
levels. Figure 5 shows Spearman’s rho for significant correlations between EPC levels and plasma factor levels in MI and GBM patients.
Blue color indicates a negative correlation between plasma factor and EPC frequency; red indicates a positive correlation. For a complete
overview (including CD133bright and CD133− HPC subtypes and correlations between EPC frequencies and plasma factors in all samples
grouped together), see Additional File 2.
and even decrease following treatment [40]. In order to
refine the HPC populations, three subgroups of these cells
are distinguished: CD133−, CD133dim, and CD133bright [25].
In the present study, we found a significant increase in
the ratio of CD133bright/CD133− HPCs in patients with MI,
compared to GBM patients (Figure 1(f)). The more primitive
phenotype of CD133bright HPCs is reportedly linked with
higher proangiogenic capacity of these cells as compared to
CD133− cells [23, 26, 27]. An increase in CD133+HPCs is seen
in acute MI [41], while levels of these cells are low in patients
with chronic vascular disease (low CD133bright/CD133− HPC
ratio [26]), suggesting that the rise in CD133bright/CD133−
HPC ratio is linked to acute ischemia.
There are various explanations for the numerical differ-
ences in EPC subsets between patients with GBM and MI.
Both conditions are associated with increased neovascular-
ization. One explanation is that MI represents a situation of
acute injury, followed by programmed regeneration, while in
neoplasia such as GBM, acute ischemic events due to, e.g.,
vessel thrombosis, occur on top of a background of chronic
hypoxia and neoplastic vascular remodeling. In acute MI, a
time course for EPC and CEC dynamics exists: within hours
after MI, a peak in CECs appears in the bloodstream, which
declines over the following weeks [36, 42]. Over the course
of 3-7 days, CD133+ cells increase, peaking around day 7, a
phenomenon that was consistent with the present analysis
[35]. Subsequently, somewhat later than CD133+ cells, HPC
levels rise [10, 13, 35].The increase in the levels of bothCD133+
cells andCD133+KDR+ cells inMIpatients suggests that these
cells are influenced by similar regulatory mechanisms and
that these EPC subtypes are particularly important in the
early phase of acute ischemia. Elevated levels of CD133+ cells
have been described before in MI and GBM and encompass
large part of the HPC population, since in these studies
no further separation of EPC subtypes was made [35, 43,
44].We found that the absolute levels of EPCs and CECs were
increased in MI and GBM, but not in the astrocytomas grade
II and III, reflecting the low level of neovascularization in
lower-grade gliomas.
The finding of higher levels of CECs in patients withGBM
and MI compared to patients with lower-grade gliomas is
corroborated by literature on patients with MI and neoplasia,
including gliomas [45–53]. The lower levels of CECs in
patients with gliomas of lower malignancy grades, in which
neovascularization is less abundant, supports the notion that
CEC levels correspond with the degree of vessel formation
and remodeling in cancer. So far, the presence of CECs was
considered to passively reflect vessel wall damage only, but
there are indications that a viable subset should be considered
as cells with potent proangiogenic and vasculogenic capac-
ities [25, 54]. These cells give rise to outgrowth endothelial
cells (OECs) when brought in cell culture and strongly stim-
ulate neovascularization, incorporate in the vessel wall, and
home to malignant tumors [55–57]. Increased levels of OEC
precursor cells correlate with a better prognosis for patients
with MI and coronary artery bypass grafts, illustrative of
their proangiogenic capacities [36, 58]. Conversely, higher
(viable) CEC levels correspond with a worse prognosis for
patients with GBM [50, 51, 59] and other cancers [53, 60, 61].
Therefore, CECs may be considered as potential therapeutic
targets in both cancer and infarction.
Limitations to any study on circulating EPCs in human
subjects include difficulties of comparing study results to
the literature, due to the lack of a clear and comparable
definition of EPC subsets and the use of different techniques
to determine or isolate EPCs. This makes it challenging to
compare findings of different studies into EPCs. For instance,
Stamm et al. [62] used magnetic beads to isolate CD133+ cells
frombonemarrow aspirates ofmyocardial infarction patients
undergoing subsequent coronary artery bypass graft. The
CD133+ bone marrow cells would in our study translate into
a mixture of CD133+ HPCs, CD133+KDR−CD34− cells and
CD133+KDR+CD34− cells. Which of these different subsets
will have been accountable for the beneficial effect in the
study of Stamm et al. remains to be determined.
The KDR+CD34−CD133− population in the present
study was not described before in the literature. How-
ever, this population needs to be distinguished from
CECs (CD34++KDR+CD45−) and from CD133+KDR+ EPCs.
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Other studies have found increased levels of CECs and
CD133+KDR+ cells in MI patients [36, 45, 63]. Inter-
estingly, we found low levels of CD34 expression in
some KDR+CD34−CD133− sorted populations (data not
shown), suggesting that the expression of CD34 may
have been too low to detect by FACS and suggest-
ing a relationship with the more frequently described
KDR+CD34+ EPC population in the literature. In our study,
the KDR+CD34−CD133−population was exclusively CD45+
indicative of hematopoietic lineage. We also found high
expression of proangiogenic factors in these cells (data not
shown). Therefore, we believe that the KDR+CD34−CD133−
EPC subset stimulates neovascularization just like other EPC
subsets. Other confounders to human EPC-related studies
are differences in age of subjects included. Younger age is
associated with higher levels of circulating EPCs [64]. We
do not believe, however, that the slight difference in age
has influenced the results in GBM vs. MI patients (Table 1).
AII/III patients are younger than GBM and MI patients,
reflecting the age difference in the occurrence of these
tumors. Young age is associated with higher circulating levels
of EPCs. The significantly lower levels of EPCs in AII/III
patients vs. GBM and MI patients emphasize the strong
effects of underlying pathology on the EPC levels. In addition,
sex differencesmay associate with circulating EPCs levels that
vary based on menstrual phase in premenopausal women
[65]). Unlike the situation in the glioma group, in the MI
group, males predominated. However, since most, if not
all, women in this study will have been postmenopausal
(based on age), we do not believe that sex will have had a
significant influence on the results either. Other confounders
like physical exercise status were not controlled for. High-
intensity physical exercise may lead to peaks in circulating
EPC and CEC levels. This could be an explanation for high
EPC level outliers in our study, particularly in the healthy
control group. Other explanations for outliers can be time
after MI (we included MI patients 1-10 days after myocardial
infarction; within this timeframe, the dynamics of EPC
and CEC levels can vary), GBM tumor characteristics (size,
level of neovascularization), and medication use (e.g., statins
can increase the levels of circulating EPCs or normalize
previously reduced levels of EPCs in the context of chronic
vascular disease and improve their function [66]).
The presence of the blood-brain barrier (BBB) or blood-
tumor barrier in the case of GBM is highly unlikely to form
an anatomical barrier relevant for EPCs. EPCs do not need
to cross the BBB into the brain parenchyma to exert their
angiogenic and vasculogenic effects. EPC entrance into the
Virchow-Robin space, directly surrounding blood vessels,
would suffice for the promotion of angiogenesis through the
production of proangiogenic factors. No entrance of EPCs
into the brain parenchyma is required for this process. Fur-
ther, the BBB is severely impaired in glioblastoma, allowing
cells to freely enter the brain [67]. Besides, even an intact BBB
would allow for the selective entrance of (inflammatory) cells
from the periphery into the parenchyma [68].
Since factors secreted by the target tissues are essential for
the recruitment and function of EPCs, we investigated a panel
of mobilization factors, chemoattractants, and angiogenic
factors in plasma along with EPC levels and found significant
differences in their mean concentrations between the patient
groups and controls. Elevated levels of these factors were
previously reported in blood and tumor tissue of patients
with GBM [69–75] and of patients with MI [76–83]. Because
the levels of vWF, MMP9, VCAM1, angiogenin, and HGF
were increased in both GBM and MI patients, but not in
the lower-grade gliomas, these factors seem to be necessary
for neovascularization in general, both under reactive and
high-grade neoplastic conditions. Together with VEGFA,
these factors were higher in GBM as compared to the lower-
grade gliomas, illustrative of their correlation with tumor
grade and level of glioma neovascularization. Increased
concentrations of vWF in GBM patients were previously
reported [42]. Interestingly, in MI patients, many of the
factors were decreased as compared to HC ( Figure 4 ). This
may in part be a reflection of chronic cardiovascular disease
and vascular dysfunction preceding the acute infarction, as
some circulating factors are already reduced in (un)stable
angina [84, 85]. An increase in levels when acute ischemia
ensues could then still remain below normal levels [86].
The increased levels of tenascin-c, vWF, MMP9, VCAM1,
and angiogenin may reflect the response to acute ischemia.
Angiogenin increases after MI, but is not elevated in patients
suffering from stable cardiovascular disease [82]. Only angio-
genin and angiopoietin-2 were increased in MI patients
compared to GBM patients, suggestive of their association
with the acute onset of ischemia occurring in MI. CXCL12
is one of the main mobilization factors for HPCs and other
EPCs. Surprisingly, CXCL12 levels were lower in all patient
groups relative to healthy controls. Reduced CXCL12 levels
were reported in patients with MI previously [87–89] and
also in experimentally induced MI in mice [88]. Our finding
of low CXCL12 levels in GBM patients seems to conflict
with literature data, where CXCL12 levels allegedly correlate
positively with glial tumor progression [37, 50, 90]. The
discrepancies may be explained by concurrent treatment, for
instance, with antiangiogenic agents [50] in these studies,
whilst in our study GBM patients were treatment-naı¨ve.
We correlated the concentrations of mobilization factors
and chemoattractants with the levels of EPC subsets in order
to investigate a potential relationship between circulating
levels of cells and factors. We found various correlations
between the plasma factors on the one hand and the EPC
subsets on the other hand ( Figure 5 ). Interestingly, in MI
patients, tenascin-c levels correlated positively with CD133+
andKDR+CD133+ levels. Tenascin-c is amatricellular protein
which is upregulated in ischemic myocardial tissue and aids
in recruiting EPCs to the infarcted area [91]. Notably, plasma
levels of tenascin-c are increased in the acute phase of MI
[92, 93] corresponding to the early phase in which CD133+
cells are released. A potential effect of plasma tenascin-
c on the mobilization of EPCs, however, remains specula-
tive.
In GBM patients, plasma levels of MMP9 correlated
positively with HPC frequencies, which seems in line with
data suggesting that MMP9 can mobilize HPCs from the
bone marrow [94]. Increased levels of CECs and vWF and
VCAM-1 are known to represent vessel damage and activated
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endothelial cells, thus explaining their elevation in GBM
patients.
How could our findings eventually be translated to novel
therapeutic targets for GBM patients? From a therapeutic
perspective, several different approaches could be chosen:
firstly, by targeting themobilization factors that lead to higher
KDR+ (and other EPC) levels in GBM patients. We found
a strong positive correlation between plasma VCAM1 levels
and KDR+ EPCs in GBM. Should further studies indicate
that VCAM1 can act as a mobilization factor for KDR+ EPCs,
anti-VCAM1 antibodies could potentially reduce circulating
KDR+ EPC levels in GBM patients. We found a strong posi-
tive correlation between plasmaMMP9 levels and circulating
HPC levels in GBM patients. From the literature, a causal
relationship between the two can be assumed since MMP9
is a known mobilization factor for HPCs (and possibly other
EPCs) [94]. Strategies to reduce plasma MMP9 levels could
decrease circulating HPC (and possibly other EPC) levels in
GBM patients. Likewise, with more of these causal relations
between plasma factors and EPC levels coming to light, more
therapeutic strategies of a similar nature can be generated.
Contrarily, in MI patients, the same strategies could
be used in an opposite fashion: administering mobilization
factors with the aim of increasing levels of circulating EPCs
(e.g., we found a strong positive correlation between plasma
tenascin-C levels and circulating levels of KDR+CD133+
and CD133+ EPCs; should tenascin-C prove to act as a
mobilization and/or homing factor to these EPCs, increasing
the level of circulating and/or myocardial tissue tenascin-
C could be beneficial to EPC mobilization and homing to
hypoxic myocardial tissue).
Secondly, the homingmechanisms of EPCs to their target
tissue can be therapeutically manipulated. In the case of
GBM, homing factors such as CXCL12 could be increased
in plasma (leading to a reduced gradient of GBM tissue-
to-blood CXCL12 levels and potentially reduced homing of
EPCs to target GBM tissue; this hypothesis would, obviously,
need to be carefully tested in further studies). Another
option could be to implant a device that captures KDR+
(and other) EPCs from the circulation of GBM patients,
thereby preventing them from reaching GBM tissue and
exerting their proangiogenic effect (a similar strategy is used
in preclinical studies in MI patients with EPC-capturing
stents to increase neovascularization [95]). To the best our
knowledge, this strategy has not been tested with the aim of
decreasing circulating levels of EPCs (and decreasing their
homing efficiency to tumor tissue) in cancer patients yet, but
could be promising.
Thirdly, the ability of EPCs to migrate to GBM tumor
tissue means that EPCs themselves could be used as ves-
sels for transport of cancer-blocking agents to the tumor
(e.g., radioactive or chemotherapeutic compounds).Whether
there is a difference between EPC subsets in their ability
to migrate to GBM tumor tissue remains to be determined
(e.g., are KDR+ EPCs better able to home to GBM tissue
than other EPCs? If so, this cell type could preferentially be
used for this strategy). This hypothesis has been postulated
before in the literature [96]. Contrarily, in the case of MI,
(KDR+CD133+, CD133+KDR−) EPCs could be altered (in
vitro) to, e.g., express higher levels of proangiogenic factors
and readministered to MI patients to aid in tissue recovery.
5. Conclusion
In conclusion, while neovascularization in both the context of
high-grade neoplasia (GBM) and acute ischemia (MI) is asso-
ciated with a rise in EPC levels, we found differences in their
relative EPC subsets. Our findings indicate that the process
of EPC-related neovascularization differs between these two
diseases. The data are supportive of the development of EPC
targeted therapeutic strategies that differ in both contexts.
In acute ischemic conditions, stimulation of EPC-induced
neovascularization is needed (increasing the circulating levels
of KDR+CD133+ and CD133+ cells). However, in GBM, inhi-
bition of EPC-induced neovascularization is necessary (spe-
cifically focusing on decreasing KDR+ cells and HPCs).
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